Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Senseonics Holdings, Inc. SENS

Healthcare  —  Medical Devices
10.00 (0.34) (3.29%) as of 25 Sep
Market cap
$546.7M
P/E
0.0×
Revenue Champion (5y) Insider Buys (last 12m)
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Senseonics Holdings, Inc. (SENS) Business Profile

Updated before January 2025

Company Overview

Senseonics Holdings, Inc. (SENS) is a medical technology company specializing in the design, development, and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes. Founded in 1996 and headquartered in Germantown, Maryland, Senseonics has been at the forefront of innovation in diabetes management. The company’s flagship product, the Eversense CGM system, has gained recognition for its unique approach to glucose monitoring, offering patients a long-term solution with implantable sensors and smartphone integration.

The leadership team at Senseonics is composed of experienced professionals with deep expertise in medical technology and diabetes care. Tim Goodnow, Ph.D., serves as the President and Chief Executive Officer, bringing decades of experience in the healthcare and medical device industries. Under his leadership, Senseonics has focused on advancing its technology and expanding its global footprint.

Core Business Segments

Senseonics operates primarily in the diabetes care market, with its core business centered around continuous glucose monitoring systems. The company’s product offerings include:

1. Eversense CGM System

The Eversense CGM system is the cornerstone of Senseonics’ product portfolio. It is the world’s first long-term implantable CGM system, designed to provide continuous glucose monitoring for up to 180 days (or 6 months) with a single sensor. Key features include:

  • Implantable Sensor: A small sensor implanted under the skin that measures glucose levels in interstitial fluid.
  • Smart Transmitter: A wearable device that communicates with the sensor and transmits glucose data to a smartphone app.
  • Mobile App: A user-friendly application that displays real-time glucose readings, trends, and alerts.

2. Eversense XL

The Eversense XL is an extended version of the Eversense CGM system, offering up to 180 days of continuous glucose monitoring. It is currently available in select international markets and has been well-received for its convenience and accuracy.

3. Support Services

Senseonics also provides a range of support services to ensure successful adoption and use of its CGM systems. These services include training for healthcare providers, patient education, and customer support.

Business Model

Senseonics’ business model revolves around the integration of innovative technology, patient-centric services, and strategic partnerships. The company generates revenue through the sale of its CGM systems, including sensors, transmitters, and associated accessories. Additionally, Senseonics collaborates with distribution partners and healthcare providers to expand its market reach.

The company’s approach to revenue generation includes:

  • Direct Sales: Selling CGM systems directly to healthcare providers and patients.
  • Partnerships: Collaborating with distributors and diabetes care organizations to increase product availability.
  • Recurring Revenue: Generating recurring revenue from sensor replacements and transmitter upgrades.

Strategic Direction

Senseonics is committed to advancing diabetes care through innovation and strategic growth. Key elements of the company’s strategic direction include:

1. Product Innovation

Senseonics is focused on enhancing its CGM technology to improve accuracy, convenience, and patient experience. The company is actively working on next-generation sensors with extended wear durations and advanced features.

2. Market Expansion

The company aims to expand its presence in international markets, particularly in Europe and Asia, where the demand for advanced diabetes management solutions is growing.

3. Sustainability Goals

Senseonics is dedicated to sustainability and reducing its environmental impact. The company is exploring ways to make its products more eco-friendly and reduce waste associated with disposable components.

4. New Product Categories

In addition to CGM systems, Senseonics is exploring opportunities to diversify its product portfolio by developing complementary technologies for diabetes care.

Competitive Landscape

Senseonics operates in a highly competitive market, facing competition from established players in the diabetes care industry. Key competitors include:

  • Dexcom, Inc.: A leading provider of CGM systems with a strong market presence and a wide range of products.
  • Medtronic: A global leader in medical technology, offering integrated diabetes management solutions, including CGM systems and insulin pumps.
  • Abbott Laboratories: Known for its FreeStyle Libre CGM system, which has gained significant market share due to its affordability and ease of use.

Despite the competition, Senseonics differentiates itself through its unique implantable CGM technology and long sensor wear duration.

Risk Factors

Senseonics faces several risks that could impact its business operations and financial performance. Key risk factors include:

  • Market Dependence: The company’s revenue is heavily reliant on the success of its CGM systems. Any decline in demand or market share could adversely affect its financial performance.
  • Regulatory Challenges: As a medical device company, Senseonics must comply with stringent regulatory requirements, which can be time-consuming and costly.
  • Supply Chain Disruptions: Disruptions in the supply chain, including shortages of critical components, could delay product manufacturing and delivery.
  • Competition: Intense competition from established players with greater resources poses a significant challenge.
  • Financial Constraints: As a relatively small company, Senseonics may face financial constraints that limit its ability to invest in research and development or expand its operations.

Recent Developments

Senseonics has made significant strides in recent years, including:

  • FDA Approval: The company received FDA approval for its Eversense E3 CGM system, which offers extended wear duration and improved accuracy.
  • Partnership with Ascensia Diabetes Care: Senseonics partnered with Ascensia to distribute its CGM systems globally, leveraging Ascensia’s extensive distribution network.
  • Technological Advancements: The company continues to invest in research and development to enhance its CGM technology and explore new applications.

Investment Considerations

Investors considering Senseonics should weigh the following factors:

Strengths

  • Innovative Technology: Senseonics’ implantable CGM systems offer a unique value proposition in the diabetes care market.
  • Growing Market: The global diabetes care market is expanding, providing significant growth opportunities.
  • Strategic Partnerships: Collaborations with established players like Ascensia enhance market reach and credibility.

Risks

  • Financial Performance: The company has yet to achieve consistent profitability, which may concern some investors.
  • Regulatory Risks: Delays or challenges in obtaining regulatory approvals could impact product launches.
  • Competitive Pressure: Intense competition from larger players with greater resources poses a risk.

Conclusion

Senseonics Holdings, Inc. is a pioneering company in the diabetes care market, offering innovative CGM solutions that improve the lives of people with diabetes. While the company faces challenges such as competition and financial constraints, its commitment to innovation and strategic growth positions it well for future success. With a growing market and a unique product offering, Senseonics has the potential to become a key player in the diabetes care industry.